Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Allogene Therapeutics Terminates Asian CAR-T Joint Venture with Overland Pharmaceuticals – Strategic Retreat from Allogeneic Cell Therapy Market in Asia

Fineline Cube May 18, 2026
Company Deals

Eli Lilly Commits $50M to UNICEF USA Alliance Targeting Non-Communicable Disease Prevention in Children Across 21 LMICs

Fineline Cube May 15, 2026
Company Deals

TenNor Therapeutics Raises $71M in Hong Kong IPO – Antimicrobial Pipeline Targets H. pylori and Implant-Associated Infections

Fineline Cube May 14, 2026
Company Deals Drug

Fosun Pharma Secures Global Rights to AriBio’s Alzheimer’s Drug AR1001 in $240M Deal – PDE-5 Inhibitor Shows Promise in Phase III

Fineline Cube May 14, 2026
Company Deals

Merck & Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform

Fineline Cube May 14, 2026
Policy / Regulatory

China Issues National Guidelines for Home Hospital Bed Services to Address Healthcare Access for Vulnerable Populations

Fineline Cube May 15, 2026
Company Drug

AstraZeneca’s Baxfendy Secures FDA Approval for Uncontrolled Hypertension – First-in-Class Aldosterone Synthase Inhibitor with Selective CYP11B2 Targeting

Fineline Cube May 18, 2026
Company Drug

Harbour BioMed Unveils Preclinical Data for LET003 – AI-Discovered ACVR2A/2B Antibody Shows Best-in-Class Potential in Obesity Combination Therapy with GLP-1 Drugs

Fineline Cube May 18, 2026
Company Deals

Ono Pharmaceutical Licenses Ionis’ Sapablursen for Global Development in Polycythemia Vera

Fineline Cube Mar 12, 2025

Japan-based Ono Pharmaceutical Co., Ltd. (TYO: 4528) announced an agreement with Ionis Pharmaceuticals, Inc. to...

Company Deals

Boehringer Ingelheim Launches One Medicine Platform with Veeva’s Development Cloud

Fineline Cube Mar 12, 2025

German pharmaceutical giant Boehringer Ingelheim and Veeva Systems (NYSE: VEEV) announced the successful launch of...

Company Drug

Biogen Initiates TRANSCEND Study for Felzartamab in Late AMR Kidney Transplant Patients

Fineline Cube Mar 12, 2025

US-based Biogen Inc. (NASDAQ: BIIB) announced the initiation of the TRANSCEND study, a global Phase...

Company Deals

MindRank Ltd Receives FDA Clearance for MRANK-106 Clinical Study in Solid Tumors

Fineline Cube Mar 12, 2025

China-based artificial intelligence (AI)-enabled drug developer MindRank Ltd announced receiving clearance from the US Food...

Company Drug

AIM Vaccine Co. Ltd Announces Market Filing for Innovative Serum-Free Rabies Vaccine

Fineline Cube Mar 12, 2025

China-based AIM Vaccine Co., Ltd (HKG: 6660) announced plans to file for market approval for...

Company Deals

TowardPi Medical Secures RMB500 Million in Series E Round for Ophthalmic Equipment Expansion

Fineline Cube Mar 12, 2025

China-based TowardPi (Beijing) Medical Technology Ltd, a leading ophthalmology equipment R&D company, has reportedly secured...

Company Deals

WuXi XDC and AbTis Partner to Advance Antibody-Drug Conjugate Innovation

Fineline Cube Mar 12, 2025

WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA...

Company Drug

Ascletis Pharma’s ASC47 Shows Positive Results in Phase Ib Study for Weight Loss

Fineline Cube Mar 12, 2025

China-based Ascletis Pharma Inc. (HKG: 1672) announced positive topline results from a Phase Ib clinical...

Company Drug

AstraZeneca’s Imfinzi Approved by NMPA for Early-Stage NSCLC Treatment

Fineline Cube Mar 11, 2025

UK-based giant AstraZeneca (NASDAQ: AZN) received approval from China’s National Medical Products Administration (NMPA) for...

Company Medical Device

Huihe Healthcare’s K-Clip Wins Chinese Approval for Tricuspid Regurgitation Treatment

Fineline Cube Mar 11, 2025

Shanghai-based Huihe Healthcare, a developer of structural heart disease intervention medical devices, announced receiving marketing...

Company

Harbour BioMed Appoints Michael D. Patten as Chief Strategy Officer to Lead Global Growth

Fineline Cube Mar 11, 2025

China-based Harbour BioMed (HKG: 2142) announced the appointment of Michael D. Patten as Chief Strategy...

Company Deals

Genmab’s HexaBody-CD38 Clinical Development Halted After J&J Opt-Out

Fineline Cube Mar 11, 2025

Denmark-based Genmab A/S (NASDAQ: GMAB) announced that US giant Johnson & Johnson (J&J, NYSE: JNJ)...

Company Drug

Sichuan Kelun-Biotech’s Sacituzumab Tirumotecan Wins New NMPA Approval for NSCLC

Fineline Cube Mar 11, 2025

China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced receiving another indication approval from the...

Company

Illumina Responds to Chinese MOFCOM Notice Amid Sequencing Instrument Export Ban

Fineline Cube Mar 11, 2025

US major Illumina (NASDAQ: ILMN), which was included in a list of unreliable entities issued...

Company Drug

Huadong Medicine Seeks Regular Approval for Elahere in Ovarian Cancer Treatment

Fineline Cube Mar 11, 2025

China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that its application for converting conditional to...

Company Digital

Hansoh Pharmaceutical’s Ameile Wins New NMPA Approval for Advanced NSCLC Treatment

Fineline Cube Mar 11, 2025

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced receiving another indication approval from the...

Company Deals

IMEIK Technology Development Co.,Ltd Acquires Majority Stake in REGEN Biotech via Joint Venture

Fineline Cube Mar 11, 2025

China-based IMEIK Technology Development Co.,Ltd (SHE: 300896) announced the establishment of Imeik International Limited, a...

Company Drug

Lundbeck’s Amlenetug Receives Orphan Drug Designation in Japan for Multiple System Atrophy

Fineline Cube Mar 11, 2025

Denmark-based pharmaceutical company Lundbeck A/S (OTCMKTS: HLUBF) announced receiving Orphan Drug Designation (ODD) from Japan’s...

Company Deals

Shenzhen GeneMind Biosciences Partners with Precisiongenes for Molecular Diagnostic Innovation

Fineline Cube Mar 11, 2025

China-based gene sequencer specialist Shenzhen GeneMind Biosciences Co., Ltd. has formed a partnership with compatriot...

Company Deals

Juvensis Therapeutics Secures RMB100 Million for Heart Gene Therapy Development

Fineline Cube Mar 11, 2025

Shanghai-based Juvensis Therapeutics, a specialist in anti-aging therapies, reportedly raised upwards of RMB100 million (USD13.8...

Posts pagination

1 … 199 200 201 … 667

Recent updates

  • AstraZeneca’s Baxfendy Secures FDA Approval for Uncontrolled Hypertension – First-in-Class Aldosterone Synthase Inhibitor with Selective CYP11B2 Targeting
  • Harbour BioMed Unveils Preclinical Data for LET003 – AI-Discovered ACVR2A/2B Antibody Shows Best-in-Class Potential in Obesity Combination Therapy with GLP-1 Drugs
  • Allogene Therapeutics Terminates Asian CAR-T Joint Venture with Overland Pharmaceuticals – Strategic Retreat from Allogeneic Cell Therapy Market in Asia
  • AstraZeneca and Daiichi Sankyo’s ENHERTU Secures Dual FDA Approval for HER2-Positive Early Breast Cancer – Neoadjuvant and Adjuvant Indications Supported by Landmark Phase 3 Data
  • Roche’s Tecentriq Secures FDA Approval for ctDNA-Guided Adjuvant Treatment in Muscle-Invasive Bladder Cancer – First MRD-Directed Immunotherapy with 41% Mortality Reduction
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

AstraZeneca’s Baxfendy Secures FDA Approval for Uncontrolled Hypertension – First-in-Class Aldosterone Synthase Inhibitor with Selective CYP11B2 Targeting

Company Drug

Harbour BioMed Unveils Preclinical Data for LET003 – AI-Discovered ACVR2A/2B Antibody Shows Best-in-Class Potential in Obesity Combination Therapy with GLP-1 Drugs

Company Deals

Allogene Therapeutics Terminates Asian CAR-T Joint Venture with Overland Pharmaceuticals – Strategic Retreat from Allogeneic Cell Therapy Market in Asia

Company Drug

AstraZeneca and Daiichi Sankyo’s ENHERTU Secures Dual FDA Approval for HER2-Positive Early Breast Cancer – Neoadjuvant and Adjuvant Indications Supported by Landmark Phase 3 Data

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.